/THRX

THRX Stock - Theseus Pharmaceuticals, Inc.

Q: What is the analyst price target for THRX?

Analyst price target information is not currently available for THRX.

Q: What is THRX's market cap?

Market capitalization information is not currently available for THRX.

Healthcare|Biotechnology|NASDAQ

$4.07+0.12%

+$0.01 (+0.12%) • Feb 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $4.47

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for THRX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.98

52W High$12.37

52W Low$2.05

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	N/A
Gross Profit	$-438,000	$-2,000	$-2,000	$-2,000
Gross Margin	N/A	N/A	N/A	N/A
Operating Income	$-54,086,000	$-27,336,000	$-6,836,000	$-4,942,000
Net Income	$-47,080,000	$-27,308,000	$-11,997,000	$-7,183,000
Net Margin	N/A	N/A	N/A	N/A
EPS	$-1.22	$-0.76	$-0.47	$-0.28

Company Overview

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

75%

Hold / Neutral

25%

Sell / Underperform

Analyst Consensus🟢 Bullish

3 Bullish1 Neutral/Bearish

Price Targets

$23

Average Target

↑ 457.6% Upside

Now

$22

Low

$23

Average

$24

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 14th 2023	Needham	Downgrade	Hold	-
March 16th 2023	Stifel	Initiation	Buy	$24
December 14th 2022	Needham	Initiation	Buy	$22
June 30th 2022	H.C. Wainwright	Initiation	Buy	$22

Earnings History & Surprises

THRX

Beat Rate

30%

Last 10 quarters

Avg Surprise

-203.3%

EPS vs Estimate

Beats / Misses

3/6

1 met exactly

Latest EPS

$-0.35

Q1 2024

EPS Surprise History

Q2 22

-8.0%

$-0.27vs$-0.25

Q3 22

-3.4%

$-0.30vs$-0.29

Q4 22

-11.8%

$-0.38vs$-0.34

Q1 23

+20.5%

$-0.35vs$-0.44

Q2 23

+19.0%

$-0.34vs$-0.42

Q3 23

0.0%

$-0.34vs$-0.34

Q4 23

+11.4%

$-0.31vs$-0.35

Q1 24

-6.1%

$-0.35vs$-0.33

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Aug 10, 2024	—	—	—	—
Q2 2024	May 11, 2024	—	—	—	—
Q1 2024	Mar 14, 2024	$-0.33	$-0.35	-6.1%	✗ MISS
Q4 2023	Nov 17, 2023	$-0.35	$-0.31	+11.4%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.34	$-0.34	0.0%	= MET
Q2 2023	May 11, 2023	$-0.42	$-0.34	+19.0%	✓ BEAT
Q1 2023	Mar 9, 2023	$-0.44	$-0.35	+20.5%	✓ BEAT
Q4 2022	Nov 3, 2022	$-0.34	$-0.38	-11.8%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.29	$-0.30	-3.4%	✗ MISS
Q2 2022	May 12, 2022	$-0.25	$-0.27	-8.0%	✗ MISS
Q1 2022	Mar 10, 2022	$-0.23	$-0.24	-4.3%	✗ MISS
Q4 2021	Nov 15, 2021	$-0.24	$-5.16	-2050.0%	✗ MISS
Q2 2021	Jun 30, 2021	—	$-0.19	—	—
Q1 2021	Mar 31, 2021	—	$-0.18	—	—
Q4 2020	Dec 31, 2020	—	$-0.11	—	—
Q3 2020	Sep 30, 2020	—	$-0.06	—	—

Frequently Asked Questions about THRX

What is THRX's current stock price?

Theseus Pharmaceuticals, Inc. (THRX) is currently trading at $4.07 per share. The stock has moved +0.12% today.

What is the analyst price target for THRX?

No analyst price targets are currently available for this stock.

What sector is Theseus Pharmaceuticals, Inc. in?

Theseus Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is THRX's market cap?

Theseus Pharmaceuticals, Inc. has a market capitalization of $0.18 billion, making it a small-cap company.

Does THRX pay dividends?

No, Theseus Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.